Biotech RadarJobs updated

COMPANY

Apollomics

HQ: Foster City, CA source · apollomicsinc.com ↗ · West Coast

Clinical Phase 3

Location: Foster City, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Relapsed/Refractory AML Renal Cancer Gastric Cancer Gastroesophageal Junction Adenocarcinoma NSCLC Lung Cancer Brain Tumor Glioblastoma Multiforme EGFR Gene Mutation MET Amplification Thyroid Cancer Pancreatic Cancer Colon Cancer MET Alteration MET Fusion Exon 14 Skipping Uproleselan APL-102 APL-101 PLB-1001

$12.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

  1. Raise Private placement: $10M (total, as published), announced Aug 11, 2026. Source: SEC filing. source ↗ · Form D filed Aug 19, 2026 SEC Form D ↗
  2. Raise Private equity round — Bridge Financing: $2M (total, as published), announced Apr 1, 2026. Source: SEC filing. source ↗
  3. Trial start Phase 1: A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants source ↗
  4. Trial start Phase 3: Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML source ↗
  5. Trial start Phase 1: APL-102 Capsule in Patients With Advanced Solid Tumors source ↗
  6. Trial start Phase 1: Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients source ↗
  7. Trial start Phase 2: APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors source ↗

Funding

Raised: $12.0M. Last 2 years.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT05055518APL-102 Capsule in Patients With Advanced Solid TumorsPhase 1SuspendedAug 2, 2021Oct 31, 2028 (estimated)
NCT05054543Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLPhase 3TerminatedNov 17, 2021Aug 22, 2024 (actual)
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPhase 2RecruitingSep 27, 2017Mar 30, 2026 (estimated)
NCT04839341Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML PatientsPhase 1CompletedFeb 24, 2021Jun 28, 2024 (actual)
NCT05367388A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian ParticipantsPhase 1Unknown status (ClinicalTrials.gov)May 20, 20222022-11 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback